Natera, Inc. (NASDAQ:NTRA) Shares Acquired by Cerity Partners LLC

Cerity Partners LLC increased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 27.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 86,144 shares of the medical research company’s stock after buying an additional 18,316 shares during the quarter. Cerity Partners LLC owned about 0.07% of Natera worth $10,936,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its holdings in shares of Natera by 1,073.1% during the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock valued at $7,118,000 after buying an additional 60,127 shares during the last quarter. Chartwell Investment Partners LLC lifted its holdings in Natera by 37.9% in the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the period. Baader Bank Aktiengesellschaft acquired a new stake in Natera in the second quarter worth about $478,000. Virtu Financial LLC acquired a new position in Natera during the 1st quarter valued at about $707,000. Finally, Envestnet Portfolio Solutions Inc. increased its stake in Natera by 50.6% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 13,622 shares of the medical research company’s stock valued at $1,475,000 after buying an additional 4,575 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of Natera stock opened at $168.32 on Wednesday. Natera, Inc. has a 12 month low of $53.88 and a 12 month high of $171.95. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a market cap of $22.22 billion, a PE ratio of -95.64 and a beta of 1.53. The business has a fifty day simple moving average of $132.23 and a 200-day simple moving average of $118.64.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s quarterly revenue was up 63.9% compared to the same quarter last year. During the same period last year, the company posted ($0.95) EPS. On average, sell-side analysts anticipate that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent analyst reports. Craig Hallum increased their price objective on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. TD Cowen boosted their price objective on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Morgan Stanley upped their price objective on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. UBS Group lowered their target price on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, Robert W. Baird upped their price target on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.59.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 5,024 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now directly owns 195,686 shares in the company, valued at approximately $25,141,737.28. This trade represents a 2.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gail Boxer Marcus sold 9,682 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $159.98, for a total value of $1,548,926.36. Following the completion of the transaction, the director now owns 9,704 shares in the company, valued at $1,552,445.92. This trade represents a 49.94 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,503 shares of company stock valued at $6,325,804. Corporate insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.